JP2024520693A5 - - Google Patents
Info
- Publication number
- JP2024520693A5 JP2024520693A5 JP2023574547A JP2023574547A JP2024520693A5 JP 2024520693 A5 JP2024520693 A5 JP 2024520693A5 JP 2023574547 A JP2023574547 A JP 2023574547A JP 2023574547 A JP2023574547 A JP 2023574547A JP 2024520693 A5 JP2024520693 A5 JP 2024520693A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence shown
- vegf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110623779.2 | 2021-06-04 | ||
| CN202110623779 | 2021-06-04 | ||
| PCT/CN2022/096848 WO2022253314A1 (zh) | 2021-06-04 | 2022-06-02 | 结合VEGF和Ang2的双特异性结合分子以及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520693A JP2024520693A (ja) | 2024-05-24 |
| JP2024520693A5 true JP2024520693A5 (https=) | 2025-06-10 |
Family
ID=84323888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023574547A Pending JP2024520693A (ja) | 2021-06-04 | 2022-06-02 | ＶＥＧＦとＡｎｇ２に結合する二重特異性結合分子およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240247057A1 (https=) |
| EP (1) | EP4349861A4 (https=) |
| JP (1) | JP2024520693A (https=) |
| KR (1) | KR20240023095A (https=) |
| CN (1) | CN117500828A (https=) |
| AU (1) | AU2022287100A1 (https=) |
| CA (1) | CA3221192A1 (https=) |
| IL (1) | IL309035A (https=) |
| MX (1) | MX2023014407A (https=) |
| TW (1) | TW202302633A (https=) |
| WO (1) | WO2022253314A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3231417A1 (en) * | 2021-09-10 | 2023-03-16 | Jian Shi | Anti-ang2 antibody, preparation method therefor, and application thereof |
| IL321122A (en) * | 2022-12-01 | 2025-07-01 | Innovent Biologics Suzhou Co Ltd | Formulations containing dual-specific binding molecules that bind VEGF and ANG2 and their uses |
| WO2025151018A1 (ko) * | 2024-01-12 | 2025-07-17 | 주식회사 노벨티노빌리티 | C-kit 및 vegf에 특이적으로 결합하는 이중특이적 항체 및 이의 용도 |
| WO2025228314A1 (en) * | 2024-04-29 | 2025-11-06 | Shenzhen Oculgen Biomedical Technology Co., Ltd | Ang2/vegf bispecific binding molecules |
| WO2026037352A1 (zh) * | 2024-08-13 | 2026-02-19 | 长春金赛药业有限责任公司 | 同时结合VEGF及Ang-2的Fc融合蛋白及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| AR080794A1 (es) * | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| US9527925B2 (en) * | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| SG11201408538PA (en) | 2012-07-13 | 2015-02-27 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
| WO2016073157A1 (en) * | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Anti-ang2 antibodies and methods of use thereof |
| BR112017009764A2 (pt) * | 2014-11-10 | 2018-02-20 | Hoffmann La Roche | anticorpos biespecíficos e métodos de uso em oftalmologia |
| MA49279A (fr) * | 2017-03-22 | 2020-02-05 | Hoffmann La Roche | Compositions d'anticorps optimisées pour le traitement de troubles oculaires |
| US20220185875A1 (en) * | 2019-03-18 | 2022-06-16 | Jiangsu Hengrui Medicine Co., Ltd. | Bispecific antibody specifically bound to vegf and ang2 |
-
2022
- 2022-06-02 IL IL309035A patent/IL309035A/en unknown
- 2022-06-02 MX MX2023014407A patent/MX2023014407A/es unknown
- 2022-06-02 JP JP2023574547A patent/JP2024520693A/ja active Pending
- 2022-06-02 CA CA3221192A patent/CA3221192A1/en active Pending
- 2022-06-02 TW TW111120663A patent/TW202302633A/zh unknown
- 2022-06-02 KR KR1020247000079A patent/KR20240023095A/ko active Pending
- 2022-06-02 WO PCT/CN2022/096848 patent/WO2022253314A1/zh not_active Ceased
- 2022-06-02 AU AU2022287100A patent/AU2022287100A1/en active Pending
- 2022-06-02 US US18/566,197 patent/US20240247057A1/en active Pending
- 2022-06-02 EP EP22815354.0A patent/EP4349861A4/en active Pending
- 2022-06-02 CN CN202280039743.2A patent/CN117500828A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI754800B (zh) | 新型抗ox40/pd-l1雙特異性抗體分子、新型抗vegf/gitr雙特異性抗體分子及其用途 | |
| JP2024520693A5 (https=) | ||
| CN107922495B (zh) | 结合egfrviii和cd3的双特异性抗体构建体 | |
| JP7065766B2 (ja) | 改変ｊ鎖を有する結合分子 | |
| IL270239B1 (en) | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration | |
| TWI815305B (zh) | Pd-1/vegf四價雙特異性抗體、其製備方法和用途 | |
| JP6328231B2 (ja) | 抗ｖｅｇｆ抗体およびそれを含む癌または血管新生関連疾患を予防、診断、または治療するための医薬組成物 | |
| IL319311A (en) | Low pH pharmaceutical composition containing T cells involved in antibody constructs | |
| CN114502595B (zh) | 针对脊髓灰质炎病毒受体(pvr)的抗体及其用途 | |
| JP7679399B2 (ja) | 抗ｆｌｔ３抗体及び組成物 | |
| KR20220042258A (ko) | 항 tigit 항체 및 그의 응용 | |
| AU2017292752B2 (en) | Antibodies with low immunogenicity and uses thereof | |
| JP2020534791A (ja) | 組換え二重特異性抗体 | |
| WO2023138551A1 (zh) | 抗cd3和抗cd20双特异性抗体及其用途 | |
| JP2022521305A (ja) | 抗ｐｄ－ｌ１抗体及びその使用 | |
| JP2024521701A (ja) | 抗ｃｄ１３７抗体及びその使用方法 | |
| TW202027788A (zh) | 雙特異性抗體構建體之下游加工 | |
| CN121057752A (zh) | 铰链经修饰的双特异性抗体 | |
| JP2025527160A (ja) | 多重特異性抗体およびその使用 | |
| JP7510209B2 (ja) | ヘルパーＴ細胞ＴＧＦ－βシグナルを特異的に中和する二重特異性抗体、その薬物組成物およびその使用 | |
| RU2023135796A (ru) | Биспецифическая связывающая молекула, которая связывается с vegf и ang2, и ее применение | |
| TW202434635A (zh) | 多特異性抗體及其醫藥用途 | |
| JP2026510317A (ja) | 抗ｃｌｄｎ６及び抗ｃｄ３多重特異性抗体及び使用方法 | |
| JP2026510307A (ja) | 抗ｃｄ３多重特異性抗体及びその使用方法 | |
| WO2022037582A1 (zh) | 抗cd3和抗cldn-18.2双特异性抗体及其用途 |